Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

2-Chlorodeoxyadenosine as initial therapy for advanced low grade lymphomas

V A Canfield1, J Vose, P Guiney

  • 1Department of Medicine, University of Oklahoma, Oklahoma City 73190, USA.

Leukemia & Lymphoma
|January 1, 1997
PubMed
Summary

This study found that 2-chlorodeoxyadenosine (2-CdA) is an active agent for treating low-grade non-Hodgkin

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A simple plan: chemotherapy-sparing approaches to early-stage and regional seminoma and nonseminoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Collaborating across sectors in service of open science, precision oncology, and patients: an overview of the AACR Project GENIE (Genomics Evidence Neoplasia Information Exchange) Biopharma Collaborative (BPC).

ESMO real world data and digital oncology·2026
Same author

A Single Institute Review of 4,428 Consecutive Appendiceal Resections: Incidence of Suspected and Incidental Pathology.

Irish medical journal·2026
Same author

Clinical Features of Children at Risk of Profound Autism.

Journal of autism and developmental disorders·2025
Same author

A CRISPRi Library Screen in Group B <i>Streptococcus</i> Identifies Surface Immunogenic Protein (Sip) as a Mediator of Multiple Host Interactions.

bioRxiv : the preprint server for biology·2024
Same author

Observation of magnet-induced star-like radiation of a plasma created from cancer cells in a laser trap.

European biophysics journal : EBJ·2024

Area of Science:

  • Hematology
  • Oncology
  • Clinical Pharmacology

Background:

  • Low-grade non-Hodgkin's lymphoma (NHL) requires effective primary therapies.
  • Assessing novel agents like 2-chlorodeoxyadenosine (2-CdA) is crucial for treatment advancements.

Purpose of the Study:

  • To evaluate the efficacy and safety of 2-chlorodeoxyadenosine (2-CdA) as a primary treatment for advanced low-grade lymphoma.
  • To determine the overall response rate and toxicity profile of 2-CdA in this patient population.

Main Methods:

  • A Phase II clinical trial was conducted involving 14 previously untreated patients with Stage III and IV low-grade lymphoma.
  • Patients received 2-CdA at 0.1 mg/kg/day via continuous infusion for 7 days every 28 days for 1-6 cycles.

Main Results:

Related Experiment Videos

  • An overall response rate of 75% was observed, with 1 complete response and 9 partial responses.
  • The primary toxicity was cumulative bone marrow suppression, particularly thrombocytopenia, leading to early discontinuation in 9 patients.
  • Febrile neutropenia occurred in 15 of 50 cycles, with one septic death.

Conclusions:

  • 2-chlorodeoxyadenosine (2-CdA) demonstrates significant activity in previously untreated low-grade lymphoma.
  • Cumulative myelosuppression is a major dose-limiting toxicity, necessitating further investigation into optimal dosing and scheduling.
  • Future research should explore modified regimens to mitigate toxicity while maximizing the therapeutic potential of 2-CdA.